Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for PI-Associated Hyperlipidemia in HIV-Infected Youth
NCT00663234Phase 2Terminated
- Sponsor
- IMPAACT Network
- Start
- Aug 2009
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of atorvastatin in hyperlipidemia (2 arms), sponsored by IMPAACT Network. Primary endpoints: Percentage of Participants Experiencing at Least One Treatment-related Adverse Event (AE) at 48 weeks, Percentage of Participants Experiencing at Least One Adverse Event (AE) at 48 weeks and 9 more. Started Aug 2009; status: terminated.
02
Drugs
atorvastatin
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT00663234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00663234.